Oncotarget

Reviews:

Long noncoding RNAs and neuroblastoma

Gaurav Kumar Pandey, Chandrasekhar Kanduri _

PDF |  HTML  |  Author Information  |  Order a Reprint

Oncotarget. 2015; 6:18265-18275. https://doi.org/10.18632/oncotarget.4251

Metrics: PDF 1146 views  |   HTML 846 views  |   ?  


Abstract

Gaurav Kumar Pandey1, Chandrasekhar Kanduri1

1Department of Medical Genetics, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden

Correspondence to:

Chandrasekhar Kanduri, e-mail: Kanduri.Chandrasekhar@gu.se

Keywords: noncoding RNA, neuroblastoma, MYCN, NBAT1, neuronal differentiation

Received: April 09, 2015     Accepted: May 29, 2015     Published: June 10, 2015

ABSTRACT

Neuroblastoma is a disease that affects infants and despite intense multimodal therapy, high-risk patients have low survival rates (<50%). In recent years long noncoding RNAs (lncRNAs) have become the cutting edge of cancer research with inroads made in understanding their roles in multiple cancer types, including prostate and breast cancers. The roles of lncRNAs in neuroblastoma have just begun to be elucidated. This review summarises where we are with regards to lncRNAs in neuroblastoma. The known mechanistic roles of lncRNAs during neuroblastoma pathogenesis are discussed, as well as the relationship between lncRNA expression and the differentiation capacity of neuroblastoma cells. We speculate about the use of some of these lncRNAs, such as those mapping to the 6p22 hotspot, as biomarkers for neuroblastoma prognosis and treatment. This novel way of thinking about both neuroblastoma and lncRNAs brings a new perspective to the prognosis and treatment of high-risk patients.

Author Information

Gaurav Kumar Pandey

Chandrasekhar Kanduri
Primary Contact  _


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 4251